Allergic diseases
Conditions
Interventions
Intervention group:Once a day, 6 drops each time (Bifidobacterium longum subsp. longum BB536, 1×10^9 CFU/day). The treatment course starts on the day of randomization, with continuous probiotic supple
Control group:No probiotics are used
At the same time, a placebo (containing only maltodextrin, with the same appearance and taste as the probiotic preparation but without any probiotic components) was given, using the same method as the
Sponsors
Chengdu Women and Children's Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Term cesarean-section (CS)-born infants (gestational age: >=37 weeks and =6 points on the Infant Allergy Risk Assessment Form (referenced from the Maternal and Child Health Center of Chinese Center for Disease Control and Prevention: Survey on Infant Allergy Symptoms and Risk Factors);? 5. Legal guardians of the infant agree to provide the infant’s fecal samples during the study;? 6. Legal guardians of the infant agree to participate in the study, sign the informed consent form, and comply with the required follow-up plan and complete the necessary follow-up forms.
Exclusion criteria
Exclusion criteria: 1. Mothers with severe diseases during pregnancy, including liver dysfunction, renal insufficiency, cardiovascular diseases, respiratory disorders, endocrine/metabolic disorders, or infectious diseases (e.g., hepatitis B, AIDS);? 2. Mothers with regular probiotic supplementation (=5 days/week) within 3 months before delivery;? 3. Infants who used antibiotics, hormones, or immunosuppressants before enrollment;? 4. Infants with severe congenital diseases/malformations, immune deficiency, major organ dysfunction, hereditary/metabolic diseases, or digestive tract/other infectious diseases;? 5. Infants with confirmed intolerance to other components of the study probiotic preparation;? 6. Infants or their mothers who participated in or are participating in clinical trials within the past 3 months;? 7. Infants deemed unsuitable for the study by researchers for other reasons;? 8. Infants from multiple pregnancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gut microbiota analysis;Allergic diseases incidence; | — |
Countries
China
Contacts
Public ContactChen Ke
Chengdu Women and Children's Central Hospital
Outcome results
None listed